A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

This Phase III study is testing whether a targeted lung cancer drug called almonertinib (an EGFR inhibitor) — taken after completing standard chemoradiation (chemotherapy plus radiation) — improves outcomes for people with locally advanced, inoperable (stage III) non-small cell lung cancer whose tumors have a specific genetic mutation (EGFR exon 19 deletion or L858R mutation). **You may be eligible if...** - You are 18 or older with confirmed stage III non-squamous non-small cell lung cancer that cannot be surgically removed - Your tumor has an EGFR mutation (specifically Ex19Del or L858R) - You have completed at least 2 cycles of platinum-based chemotherapy combined with radiation (54–66 Gy), finishing no more than 6 weeks ago - Your cancer did not progress during or after chemoradiation - You are in good health (WHO performance status 0–1) **You may NOT be eligible if...** - You have previously used an EGFR-targeted drug (like erlotinib, gefitinib, or osimertinib) - You have had prior chemotherapy or immunotherapy for this lung cancer outside of the standard chemoradiation - You have a history of lung scarring (interstitial lung disease) - You have ongoing significant side effects (grade 2 or above) from prior treatment - You have significant heart problems (abnormal QT interval, severe heart failure) - You have uncontrolled infections, active hepatitis B or C, or HIV - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.